Mizoribine
As of the edition of 20 October 2026, Mizoribine is a small molecule: in active development; acts on GMPS, IMPDH1 and IMPDH2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2022
- Kind
- Small molecule
- Registered trials
- 6, 0 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 2 | 0 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chong Kun Dang Pharmaceutical | Lead sponsor of trials | 2013 to now |
| Asahi Kasei Therapeutics | Lead sponsor of trials | 2014 to now |
| Sanofi | Lead sponsor of trials | 2015 to now |
| Lee's Pharmaceutical | Lead sponsor of trials | 2022 to now |